A Study of the Safety and Tolerability of MEDI1873 for Treating Adult Subjects with Select Advanced Solid Tumors

Overview

Información sobre este estudio

The purpose of this study is to evaluate the safety and tolerability of MEDI1873 for the treatment of adult subjects who have selected advanced solid tumors.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria

  • Must consent to provide an archived tumor specimen
  • Must have histologically or cytologically confirmed advanced solid tumor for recurrent or metastatic disease
  • At the time of day 1 of the study, central nervous system (CNS) metastases must have been treated and must be asymptomatic
  • Willing to provide pretreatment and on-treatment biopsies
  • Has adequate organ function
  • Females of childbearing potential and nonsterilized males who are sexually active must use effective methods of contraception

Exclusion Criteria

  • A known allergic reaction to any component of MEDI1873
  • Concurrent enrollment in another clinical study, unless it is an observational clinical study or the follow-up period of an interventional study
  • Receiving any anticancer therapy within 4 weeks prior to the first dose of MEDI1873 or in the case of mAbs, 6 weeks prior to the first dose of MEDI1873
  • Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment
  • Receiving a live, attenuated vaccine within 28 days prior to the first dose of investigational product
  • Unresolved toxicities from prior anticancer therapy
  • Any condition that, in the opinion of the investigator or sponsor, would interfere with evaluation of the investigational product

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus Contacto

Scottsdale/Phoenix, Ariz.

Investigador principal de Mayo Clinic

Ashish Chintakuntlawar, M.B.B.S., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

Rochester, Minn.

Investigador principal de Mayo Clinic

Ashish Chintakuntlawar, M.B.B.S., Ph.D.

Cerrado para la inscripción

Contact information:

Cancer Center Clinical Trials Referral Office

855-776-0015

More information

Publicaciones

Publications are currently not available
.
CLS-20251483

Mayo Clinic Footer